Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Jan 31.
Published in final edited form as: J Am Stat Assoc. 2024 Jan 31;119(546):811–824. doi: 10.1080/01621459.2023.2297467

Estimating cell-type-specific gene co-expression networks from bulk gene expression data with an application to Alzheimer’s disease

Chang Su a,b, Jingfei Zhang c, Hongyu Zhao b,*
PMCID: PMC11394578  NIHMSID: NIHMS1966163  PMID: 39280354

Abstract

Inferring and characterizing gene co-expression networks has led to important insights on the molecular mechanisms of complex diseases. Most co-expression analyses to date have been performed on gene expression data collected from bulk tissues with different cell type compositions across samples. As a result, the co-expression estimates only offer an aggregated view of the underlying gene regulations and can be confounded by heterogeneity in cell type compositions, failing to reveal gene coordination that may be distinct across different cell types. In this paper, we introduce a flexible framework for estimating cell-type-specific gene co-expression networks from bulk sample data, without making specific assumptions on the distributions of gene expression profiles in different cell types. We develop a novel sparse least squares estimator, referred to as CSNet, that is efficient to implement and has good theoretical properties. Using CSNet, we analyzed the bulk gene expression data from a cohort study on Alzheimer’s disease and identified previously unknown cell-type-specific co-expressions among Alzheimer’s disease risk genes, suggesting cell-type-specific disease mechanisms.

Keywords: bulk RNA-seq, cell-type-specific analysis, deconvolution, gene co-expression networks, sparse covariance estimation

1. Introduction

Alzheimer’s disease is a neurodegenerative disorder that causes progressive and irreversible loss of neurons in the brain (Winblad et al., 2016). It is estimated to affect 5.8 million people in the United States and has become the fifth leading cause of death among Americans over 64 years old (Alzheimer’s Association, 2019). Genetic factors are known to play an important role in Alzheimer’s disease, with an estimated heritability of 58–79% for late-onset Alzheimer’s disease, and large scale genome wide association studies (GWAS) have implicated dozens of regions of the human genome for their relevance for Alzheimer’s disease (Sims et al., 2020). To understand the mechanisms of these disease associated risk genes and the pathogenesis of Alzheimer’s disease, gene co-expression networks have been widely employed (Zhang et al., 2013; Wang et al., 2016; Mostafavi et al., 2018; Meng and Mei, 2019; Wan et al., 2020; Wang et al., 2021b).

Gene co-expression networks characterize correlations of gene expression levels across biological samples and co-expressed genes may be regulated by the same transcription factors, functionally related, or involved in the same pathways (Gaiteri et al., 2014). Gene co-expression networks have been extensively used to identify functional modules of genes and pathways, which were further associated with disease phenotypes (Wang et al., 2016; Mostafavi et al., 2018; Meng and Mei, 2019; Wang et al., 2021b). For example, a gene co-expression analysis in Zhang et al. (2013) identified TYROBP as a key regulator in an immune related module upregulated in late-onset Alzheimer’s disease, which was recapitulated in vivo in mice. In this paper, the links in a co-expression network characterize associations of gene expression levels across samples and do not necessarily imply gene regulatory relationships.

While the literature on gene co-expression networks is rapidly growing, most co-expression analyses to date have been performed on data collected from bulk tissue samples that aggregated the expression profiles from different cell types. As a result, the estimated co-expression networks only offer an aggregated view of the underlying gene regulations, while gene regulations may differ considerably in different cell types (Heintzman et al., 2009), and the co-expression estimates can be dominated by signals from the more abundant cell types. Moreover, as different bulk samples may have different cell type compositions, the observed co-expressions may be confounded with cell type proportions. For example, consider two genes that are both highly expressed in one cell type but are not co-expressed at the cell type level. Bulk sample data may show that these two genes co-express as their expression levels co-vary with the proportion of this specific cell type in the bulk sample. Meanwhile, increasing evidence suggests cell-type-specific pathogenesis of Alzheimer’s disease (De Strooper and Karran, 2016). For example, neuroinflammation represents a key causal pathway in Alzheimer’s disease and involves primarily glial cells in the brain including microglia and astrocytes (Heneka et al., 2015); myelination is also implicated in the disease, which is mainly contributed by oligodendrocytes (Cai and Xiao, 2016). To gain a more accurate and comprehensive view of the biological processes underlying Alzheimer’s disease, a better approach is to estimate cell-type-specific co-expression networks.

Cell-type-specific co-expressions can possibly be estimated from single cell RNA sequencing (RNA-seq) data (Hwang et al., 2018) that measure expression profiles in single cells. However, these data are much more limited in the number of biological samples analyzed (Stower, 2019), have high noises and sparsity due to low coverage and biological noises (Kiselev et al., 2019), and may be biased due to cell isolation and sequencing protocols (Denisenko et al., 2020). For example, a recent single cell study on Alzheimer’s disease has profiled 18 samples and conducted a gene co-expression analysis after aggregating the sparse expression data over single cells (Morabito et al., 2021). The co-expression analysis findings were only made for oligodendrocytes and did not cover astrocytes and microglia which are arguably more closely related to the Alzheimer’s disease mechanisms, potentially due to their lower proportions in the brain and the high sparsity of single cell data. Real data results in Section 4 show that cell-type-specific co-expressions estimated from single cell RNA-seq data are noisy and co-expressions are often only seen in the highly abundant cell types. Instead of resorting to single cell data for estimating cell-type-specific co-expressions in Alzheimer’s disease, we consider the use of bulk sample data in this paper.

1.1. The ROSMAP Study on Alzheimer’s Disease

Our work focuses on the bulk RNA-seq data from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP; Bennett et al., 2018), a clinical-pathologic cohort study of Alzheimer’s disease. In the ROSMAP study, postmortem brain samples from n=541 subjects were collected from the grey matter of dorsolateral prefrontal cortex, a brain region heavily implicated in Alzheimer’s disease pathology. Single cell data from the same study found eight common brain cell types in these tissue samples (Mathys et al., 2019) including excitatory neuron, astrocyte, oligodendrocyte, microglia, inhibitory neuron, endothelial cell, pericyte, oligodendrocyte precursor cell, where the average estimated proportions for the first four major cell types in the bulk RNA-seq samples are 0.50, 0.20, 0.19, 0.08, respectively, adding together to 97% (see Section 4).

While the large sample size of the ROSMAP study facilitates a better estimation of gene co-expressions in the brain (Mostafavi et al., 2018), co-expressions directly estimated via correlations of the aggregated bulk samples are subject to the issues discussed before, including confounding by cell type proportions and estimates dominated by signals from the more abundant cell types. In particular, these estimates may fail to reveal the biological functions and pathways in different brain cell types that underlie the pathogenesis of Alzheimer’s disease. This motivates our study that aims to estimate cell-type-specific co-expression networks from bulk RNA-seq data, by leveraging the estimated cell type proportions in bulk samples (Newman et al., 2019), and to examine the estimated networks in cell types relevant to Alzheimer’s disease for a better understanding of disease mechanisms.

1.2. Existing Methods and Our Approach

There is a recently growing literature on decomposing bulk gene expression profiles into cell-type-specific profiles (Cobos et al., 2020). Using the bulk data, various methods are available to infer mean expression levels in each cell type (Newman et al., 2019) and to infer cell type proportions (Abbas et al., 2009; Wang et al., 2019; Newman et al., 2019; Tang et al., 2020; Jew et al., 2020; Yang et al., 2021). More recently, methods have been proposed to infer cell-type-specific expressions in each sample, such as CIBERSORTx (Newman et al., 2019), bMIND (Wang et al., 2021a), and ENIGMA (Wang et al., 2021c). For each cell type, these methods offer an indirect way to estimate the co-expressions, by calculating the correlations of estimated expression profiles across samples. However, we show in Sections 3 and 4 that these methods rely on either restrictive assumptions, or high-quality external information that is not readily available in practice.

In our work, we consider a different statistical approach and propose a flexible method to estimate Cell-type-Specific gene co-expression Networks using bulk gene expression data, and call this method CSNet. Specifically, we formulate the problem as estimating the means and covariances of unknown densities from different cell types using data (i.e., bulk samples) generated from a convolution of these densities with varying compositions. Our method CSNet does not make specific assumptions on the distributions of expression levels from different cell types, and it overcomes the computational challenge in estimating the covariances in a convolution of densities, especially when the number of genes is large, through a novel least squares approach that is efficient to implement and has good theoretical properties. We further propose a sparse estimator with SCAD penalty in the high dimension regime where the number of genes p can far exceed the sample size n.

Using CSNet, we analyzed the bulk RNA-seq data from the ROSMAP study and estimated gene co-expression networks for eight common cell types in the brain, including four major cell types, excitatory neuron, oligodendrocyte, astrocyte and microglia, on genes with known genetic risk for Alzheimer’s disease, where modules of risk genes that uniquely co-express in astrocytes and microglia were uncovered. In contrast, the estimator based on cell-type-specific expression levels imputed by Wang et al. (2021a) generated co-expression estimates that were similar in all cell types and did not identify any cell-type-specific modules (see Figure S10(a)). Both astrocyte and microglia are cell types that are less abundant (less than 20%), and the co-expressions estimated from single cell RNA-seq data showed no correlations in these two cell types (see Figure S10(b)). We have also considered gene sets that function primarily in specific cell types to validate CSNet and conducted several sensitivity analyses to further validate our results.

The rest of the paper is organized as follows. Section 2 introduces the data problem and discusses estimating cell-type-specific co-expressions from bulk samples using CSNet. Section 3 reports the simulation results, and Section 4 conducts an analysis of cell-type-specific gene co-expression networks on gene sets with known cell-type-specific functions and on an Alzheimer’s disease risk gene set using bulk RNA-seq data from the ROSMAP study. Section 5 concludes the paper with discussions.

2. Model and Estimation

2.1. Problem Formulation

Suppose we have expression data x1,,xnp collected from n bulk RNA-seq samples across p genes. We assume that there are K cell types, and the observed bulk level expression is the sum of these K cell types written as

xi=k=1Kπikxi(k), (1)

where πik and xi(k) represent the proportion and expression profile of the kth cell type in the ith sample, respectively. Let xi(k) be independent from a multivariate distribution with mean μ(k)p and covariance Σ(k)p×p, where μ(k) and Σ(k) characterize the cell-type-specific mean gene expression and co-expression, respectively. Correspondingly, we can write

𝔼xi=k=1Kπikμ(k),Covxi=k=1Kπik2Σ(k)+kkKπikπikΣk,k, (2)

where Σk,k=Covxi(k),xik. As the gene regulation mechanisms in functionally distinct cell types are different (Heintzman et al., 2009), it is expected that the within-cell-type covariance k=1Kπik2Σ(k) is much larger than the across-cell-type covariance kkKπikπikΣk,k. This assumption is supported by our real data analysis using a large single nucleus RNA-seq data from brain tissues in Fujita et al. (2022) with 436 individuals (see Section S2). Hence, to reduce model complexity, we assume kkKπikπikΣk,k=0 and consider

𝔼xi=k=1Kπikμ(k),Covxi=k=1Kπik2Σ(k). (3)

Also using the data set in Fujita et al. (2022), we demonstrate that our method is not sensitive to the misspecification of assuming the across-cell-type covariance kkKπikπikΣk,k=0. Details of this analysis are included in Section S2. As Σ(k) does not relate directly to the strength of gene co-expressions, due to heterogeneity in variances, we further consider correlation matrices in our analysis denoted as R(k)=Dk1/2Σ(k)Dk1/2, where Dk is a p×p diagonal matrix with the same diagonal as Σ(k).

Denote [m]={1,2,,m} for a positive integer m. We shall assume the cell type proportions πik’s in (3) are given in the ensuing development, and later demonstrate in experiments that our method is not sensitive to biases and errors in πik’s; see results in Sections 3.2, A5.1 and discussions in Section 5. To infer πik’s from bulk samples, many methods have been developed that utilize cell type marker genes (i.e., genes that are only highly expressed in one cell type of interest) with expression profiles gathered from pure cell types (Newman et al., 2015; Li et al., 2016) or single cell RNA-seq data (Wang et al., 2019; Newman et al., 2019; Jew et al., 2020; Dong et al., 2021; Yang et al., 2021; Chu et al., 2022). In these methods, the proportions πik’s are estimated by, for example, nonnegative least squares (Wang et al., 2019) or support vector regression (Newman et al., 2019). Given the bulk samples xii[n] and cell type proportions πiki[n],k[K], our goal is to estimate the cell-type-specific correlations R(k)k[K].

2.2. Estimating R(k) with Large p

It is easily seen from (1) and (3) that each bulk sample xi is from a convolution of K distributions. In this case, estimating Σ(k)k[K] from xii[n] is very challenging. For example, even in the simple Gaussian case, the log likelihood function is, up to a constant,

i=1nlogk=1Kπik2Σ(k)i=1ntrk=1Kπik2Σ(k)1zizi,

where tr() denotes the trace of a matrix and zi=xi𝔼xi. This loglikelihood is not convex or biconvex with respect to Σ(k)k[K], and cannot be directly optimized using existing iterative algorithmic solutions such as EM and coordinate descent. To our knowledge, there are no existing methods that can effectively estimate the covariances in a convolution of densities.

To tackle this challenge, we propose a novel moment-based approach that is efficient to implement and flexible, in that it does not assume the distributions from the K cell types to be known or of the same type. The proposed approach, named CSNet, first estimates R(k) efficiently in an element-wise fashion and then applies a thresholding step, in the case of a large p, to give a sparse estimator. Next, we introduce the CSNet estimator.

Letting μ(k)=μ1(k),,μp(k) and Σ(k)=σjj(k)p×p, (1) and (3) together imply

xij=k=1Kπikμj(k)+zij,j[p], (4)
zijzij=k=1Kπik2σjj(k)+ϵijj,j,j[p], (5)

where 𝔼zij=0 and 𝔼ϵijj=0. This formulation facilitates an efficient least squares estimation procedure to be detailed in the next paragraph. Note that (4)–(5) hold generally without parametric assumptions on the distributions from the K cell types.

Denote xj=x1j,,xnj and P1=πikn×K. Equation (4) entails estimation of the cell-type-specific mean μ(k) via

μˆj(k)=P1P11P1xjk,j[p],k[K], (6)

where [x]k is the kth entry in xK. Let zˆij=xijk=1Kπikμˆj(k) and zˆj=zˆ1j,,zˆnjn. Denoting P2=πik2n×K, equation (5) entails estimation of the cell-type-specific covariance σjj(k) via

σˆjj(k)=P2P21P2zˆjzˆjk,j,j[p],k[K], (7)

where ° denotes element-wise product. Then, the cell-type-specific correlation Rˆjj(k) is estimated as

Rˆjj(k)=σˆjj(k)/σˆjj(k)σˆjj(k),j,j[p],k[K]. (8)

In Section S6.2, we show that element-wisely Rˆjj(k) is consistent with a n-convergence rate under certain regularity conditions. In our implementation, as cell-type-specific means μj(k)’s and variances σjj(k)’s are positive parameters, we adopt non-negative least squares (NNLS) to improve their estimation accuracy in finite samples. To reduce the variability in the estimates of cell-type-specific covariances σjj(k)’s, we further consider a weighted least squares approach with carefully chosen weights (see details in Section S3.1).

Though each entry in the correlation matrix estimated in (8) has a n-convergence rate, the accumulated errors across Op2 entries in R(k) can be excessive, especially as the number of genes p often far exceeds the sample size n in co-expression network analysis, which can negatively impact downstream analyses such as ranking, principal component analysis or clustering. This same challenge also arises in estimating large sample covariance (Bickel and Levina, 2008a,b; Rothman et al., 2008, 2009) and correlation matrices (El Karoui, 2008; Jiang, 2013). To facilitate estimability and interpretability, we assume that Σ(k) (or equivalently R(k)) is approximately sparse for all k; see the definition of approximate sparsity in Assumption 2 (Section S1). Sparsity is plausible in our data problem, as gene co-expressions are expected to be sparse when p is large (Zhang and Horvath, 2005).

Based on R(k), the proposed CSNet estimator computes sparse cell-type-specific correlation estimates via thresholding. Specifically, CSNet applies an element-wise SCAD (Fan and Li, 2001) thresholding operator to R(k), written as 𝒯λkR(k)), with the j,jth thresholded entry calculated as

𝒯λkR(k)jj=signRˆjj(k)×Rˆjj(k)λk+Rˆjj(k)2λkλk+a1a2Rˆjj(k)2λkRˆjj(k)2λk,aλkRˆjj(k)otherwise, (9)

where λk is a tuning parameter and we discuss its selection in Section 2.3. As has been well established in the sparse covariance estimation literature (e.g. Bickel and Levina, 2008a,b; Rothman et al., 2008, 2009), the thresholding procedure is easy to implement and enjoys good theoretical properties. Moreover, the SCAD thresholding has been found to give better numerical performances when compared to soft or hard thresholding (Rothman et al., 2009). We set a=3.7 in our experiments as recommended by Fan and Li (2001). The thresholds λk’s may differ across different cell types to accommodate varying sparsity among different cell types. We note that the λk’s can be selected separately (without a joint tuning) in our tuning procedure (see Section 2.3), which is an attractive computational property of our procedure. In Section S1, we show the convergence rates of CSNet, i.e., 𝒯λkR(k), in spectral and Frobenius norms, and establish its selection consistency.

As with all thresholding approaches, 𝒯λkR(k) is not guaranteed to be positive definite; see more discussions in Section 5 on considerations for positive definiteness. To ensure the finite sample validity of correlation estimates, we threshold the correlation estimates to be within [1,1] in our experiments.

2.3. Time Complexity and Parameter Tuning

We first discuss the time complexity of solving (7) for all entries in covariance matrices. Though (7) is computed element-wisely, the matrix P2P21P2K×n is common and only needs to be calculated once. Hence, entries in Σ1,,ΣK can be estimated efficiently via P2P21P2U, where U is an n×p2 matrix with the jj th column set to zˆjzˆj. Correspondingly, the time complexity of estimating Σ1,,ΣK is OKnp2, while that of a naive sample covariance estimation is Onp2. As the number of cell types K is usually small, the two computing times are comparable.

Next, we discuss parameter tuning. In our procedure, the tuning parameters λk’s are selected using cross validation or, if available, an independent validation data set. Here, we introduce the cross validation procedure and note that selection with a validation data set can be carried out similarly. We randomly split the data into two equal-sized pieces and estimate for each piece, the cell-type-specific correlation matrices as in (8). We denote the estimated correlation matrices from these two data splits as R1(k) and R2(k),k[K], respectively. For each k, the tuning parameter λk is selected by minimizing 𝒯λkR1(k)R2(k)F2+𝒯λkR2(k)R1(k)F2 among a set of working values, where F denotes the Frobenius norm. We consider two equal sized data splits as sufficient samples are needed to estimate R1(k) and R2(k) well. This procedure is similar to what was proposed in Bickel and Levina (2008a), where the theoretical justification was provided, and it is found to give a good performance in our numerical experiments. In practice, this procedure can be overly conservative for less abundant cell types, as the estimates R1(k) and R2(k) can be very noisy (see Figure S11). To mitigate this issue, we propose to further consider a one standard error rule for selecting the tuning parameters in less abundant cell types (see Section S3.2). An attractive feature of our proposed tuning procedure is that λk’s are selected separately without the need of a joint tuning, further reducing the computational cost.

3. Simulation Studies

We first investigate the finite sample performance of CSNet and compare it with three existing methods, and then conduct a sensitivity analysis to examine the performance of CSNet when the provided cell type proportions have biased noises.

3.1. Comparing CSNet with Other Methods

We consider two classes of estimators: dense correlation estimators without thresholding and sparse correlation estimators that implement SCAD thresholding. For dense correlation estimators, we consider the estimator calculated using bulk samples, referred to as d–Bulk, the cell-type-specific estimator in (8) without sparsity, referred to as d–CSNet, estimators that compute the sample correlations of the cell-type-specific expressions estimated by Wang et al. (2021a) and Wang et al. (2021c), referred to as bMIND and ENIGMA, respectively. We apply SCAD thresholding to the above four dense estimators and obtain sparse correlation estimators referred to as Bulk, CSNet, s–bMIND and s–ENIGMA, respectively. For these sparse estimators, tuning parameters were selected using the same cross validation procedure to facilitate a fair comparison. The method bMIND considers a Bayesian mixed effects model that constructs priors using single cell data and estimates cell-type-specific expressions in each sample with posterior means. In our experiment, it was evaluated with non-informative priors to be comparable with the other methods, which do not depend on prior knowledge. We also consider informative priors for bMIND in Tables S2 and S5 in the supplement and the results remain similar. The method ENIGMA (Wang et al., 2021c) is an optimization-based method that estimates cell-type-specific expressions for each sample by minimizing the difference between estimated and observed bulk data and it was evaluated under the default parameter setting (see more details in Section S4). We chose to not compare with CIBERSORTx high-resolution expression purification (Newman et al., 2019) as it is applicable only when there are both case and control samples in the data. All methods under comparison were supplied with true cell type proportions. Sensitivity analysis with biased noises in cell type proportions is presented in Section 3.2.

We simulate n bulk samples of dimension p following xi=k=1Kπikxi(k) in (1) with K=2 cell types and πi1’s i.i.d from Beta(2,1). Correspondingly, cell type 1(m=2/3) is on average twice as abundant as cell type 2(m=1/3), where m denotes the average cell type proportions. We simulate xi(k)’s from multivariate negative binomial distributions, resembling read counts from bulk RNA-seq data (Love et al., 2014), with mean μ(k)’s and covariance matrices Σ(k)’s specified as follows. The p genes are divided into three equal-sized sets, denoted as V1,V2 and V3; genes in V1 and V2 are set to co-express in cell types 1 and 2, respectively, while all other correlations are set to zero (see the left panel in Figure 1). For the co-expressed genes in V1 or V2, two types of structures are considered, including a truncated AR(1) structure with ρjj=0.8jj for jj10, and a correlation structure estimated from real single cell RNA-seq data for jjV1 or V2 (see details in Section S3.3). We set logσjj(1)=8 for all j, logσjj(2)=8 for jV1,V2 and logσjj(2)=9 for jV3 with sequencing depth set to S=6×107 to mimic highly-expressed protein-coding genes in real sequencing data. The mean μ(k) is set to be a function of Σ(k) (see details in Section S3.4), consistent with the observation in real data that higher expression levels are often associated with larger variances. To simulate correlated negative binomial random variables as specified, we combine a marginal negative binomial model (Section S3.4) and a copula-based approach that can simulate multivariate count data following a pre-specified correlation matrix (Tian et al., 2021; Sun et al., 2021). The tuning parameters for CSNet and Bulk are selected following Section 2.3 and the suggested procedure in Rothman et al. (2009), respectively, both using a validation data set with the same size as the observed samples. We consider network sizes p=100, 200 and sample sizes n=150, 600.

Fig. 1.

Fig. 1

Correlation matrix estimate in one data replicate with p=100 and n=150, under a negative binomial distribution with a truncated AR(1) correlation structure in V1 or V2 (see Section 3). From left to right: true correlation matrices, estimates from Bulk, CSNet, s–bMIND and s–ENIGMA. Note the Bulk estimate is not cell-type-specific.

To evaluate the estimation accuracy, we report the estimation errors in the Frobenius norm R(k)R(k)F and operator norm R(k)R(k), where R(k), with a slight overuse of notation, denotes the estimate of R(k) obtained by various methods. For sparse estimators, we also report the true positive rate (TPR) and false positive rate (FPR), which evaluate the selection accuracy of nonzero entries in R(k)’s. Tables 1 and 2 report the average criteria under the truncated AR(1) model for sparse and dense estimators, with standard deviations in the parentheses, over 200 data replications. Table 1 shows that CSNet achieved the best performance in terms of both estimation accuracy and selection accuracy. CSNet also performed the closest to an oracle estimator that benchmarks the performance if true cell-type-specific expressions within each bulk sample were available (Table S1). In the supplement, we demonstrate in Tables S2 that even with informative priors derived from simulated cell-type-specific data, CSNet still performed better than s–bMIND. Table 2 further shows that d–CSNet yielded satisfactory performance among dense estimators. The errors of bMIND can be smaller than d–CSNet in some cases. This is because the true signal is highly sparse and bMIND tended to give a biased but less variable estimate (see Figure S5). In Table S3, we show that d–CSNet outperformed bMIND when denser signals were considered. We also demonstrate in Table S4 that when the true co-expressions were set by a correlation structure estimated from real data, CSNet again achieved the best performance among all methods.

Table 1.

Evaluation criteria of sparse estimators with varying sample size n and network size p under a negative binomial distribution with a truncated AR(1) correlation structure for genes in V1 or V2 (see Section 3). The four sparse estimators under comparison are Bulk, CSNet, s–bMIND and s–ENIGMA. We use F-norm to denote the Frobenius norm and Op.-norm to denote the operator norm. Marked in boldface are those achieving the best evaluation criteria in each setting.

Cell type 1 (m = 2/3) Cell type 2 (m = 1/3)
n p Method F-norm Op.-norm FPR TPR F-norm Op.-norm FPR TPR
150 100 Bulk 28.11 (0.14) 27.29 (0.12) 0.26 (0.03) 0.79 (0.06) 30.16 (0.15) 27.29 (0.12) 0.28 (0.03) 0.39 (0.06)
CSNet 4.34 (0.34) 2.36 (0.39) 0.11 (0.01) 0.75 (0.06) 7.56 (0.41) 4.53 (0.44) 0.08 (0.01) 0.51 (0.07)
s–bMIND 5.97 (0.55) 4.13 (0.41) 0.14 (0.03) 0.59 (0.06) 11.76 (0.58) 6.60 (0.04) 0.09 (0.05) 0.08 (0.06)
s–ENIGMA 25.07 (0.76) 23.51 (0.81) 1.00 (0.00) 1.00 (0.00) 31.59 (0.74) 29.81 (0.78) 1.00 (0.00) 1.00 (0.00)
200 Bulk 54.74 (0.19) 53.79 (0.18) 0.20 (0.02) 0.73 (0.05) 56.89 (0.18) 53.79 (0.18) 0.22 (0.02) 0.32 (0.04)
CSNet 7.07 (0.35) 3.10 (0.30) 0.07 (0.01) 0.69 (0.05) 11.84 (0.34) 5.37 (0.26) 0.05 (0.01) 0.44 (0.04)
s–bMIND 8.48 (0.55) 4.36 (0.34) 0.08 (0.01) 0.60 (0.05) 17.17 (0.53) 6.97 (0.02) 0.05 (0.02) 0.05 (0.03)
s–ENIGMA 48.97 (0.93) 46.45 (0.99) 1.00 (0.00) 1.00 (0.00) 62.01 (0.98) 59.22 (1.05) 1.00 (0.00) 1.00 (0.00)
600 100 Bulk 28.05 (0.07) 27.37 (0.06) 0.30 (0.04) 0.95 (0.03) 30.05 (0.08) 27.37 (0.06) 0.31 (0.04) 0.67 (0.05)
CSNet 2.08 (0.20) 0.99 (0.20) 0.10 (0.02) 0.93 (0.03) 3.69 (0.27) 1.88 (0.31) 0.10 (0.01) 0.80 (0.05)
s–bMIND 4.49 (0.15) 3.37 (0.20) 0.35 (0.03) 0.79 (0.03) 10.18 (0.34) 5.87 (0.25) 0.21 (0.05) 0.50 (0.09)
s–ENIGMA 18.77 (0.34) 17.68 (0.36) 1.00 (0.00) 1.00 (0.00) 25.26 (0.35) 23.89 (0.36) 1.00 (0.00) 1.00 (0.00)
200 Bulk 54.64 (0.09) 53.93 (0.08) 0.23 (0.03) 0.94 (0.02) 56.88 (0.10) 53.93 (0.08) 0.24 (0.03) 0.61 (0.04)
CSNet 3.41 (0.21) 1.30 (0.19) 0.07 (0.01) 0.91 (0.03) 5.89 (0.29) 2.40 (0.25) 0.07 (0.01) 0.76 (0.04)
s–bMIND 5.07 (0.20) 2.76 (0.15) 0.15 (0.01) 0.83 (0.03) 14.98 (0.41) 6.17 (0.20) 0.11 (0.02) 0.49 (0.06)
s–ENIGMA 36.25 (0.51) 34.92 (0.53) 1.00 (0.00) 1.00 (0.00) 49.17 (0.48) 47.33 (0.49) 1.00 (0.00) 1.00 (0.00)

Table 2.

Evaluation criteria of dense estimators under the same setting as Table 1. The four dense estimators under comparison are d–Bulk, d–CSNet, bMIND and ENIGMA.

n 150 600
Cell type 1 (m=2/3) 2 (m=1/3) 1 (m=2/3) 2 (m=1/3)
p Method F norm Op. norm F norm Op. norm F norm Op. norm F norm Op. norm
100 d–Bulk 29.02 (0.18) 27.77 (0.18) 30.78 (0.19) 27.78 (0.19) 28.30 (0.07) 27.49 (0.07) 30.10 (0.08) 27.49 (0.07)
d–CSNet 11.80 (0.23) 4.15 (0.39) 20.01 (0.58) 7.34 (0.63) 5.80 (0.10) 1.85 (0.16) 9.52 (0.19) 3.08 (0.29)
bMIND 10.80 (0.24) 4.89 (0.25) 15.57 (0.36) 6.62 (0.39) 7.08 (0.08) 4.60 (0.12) 10.93 (0.31) 5.58 (0.20)
ENIGMA 25.07 (0.76) 23.51 (0.81) 31.59 (0.74) 29.81 (0.78) 18.77 (0.34) 17.68 (0.36) 25.26 (0.35) 23.89 (0.36)
200 d–Bulk 56.76 (0.24) 54.80 (0.25) 58.67 (0.23) 54.81 (0.25) 55.18 (0.09) 54.17 (0.09) 57.16 (0.10) 54.18 (0.09)
d–CSNet 23.66 (0.27) 6.95 (0.43) 40.22 (0.74) 12.96 (0.95) 11.63 (0.12) 2.97 (0.21) 19.17 (0.20) 5.15 (0.33)
bMIND 19.84 (0.22) 5.81 (0.31) 26.15 (0.35) 8.78 (0.63) 11.43 (0.11) 4.97 (0.14) 17.27 (0.34) 5.73 (0.18)
ENIGMA 48.97 (0.93) 46.45 (0.99) 62.01 (0.98) 59.22 (1.05) 36.25 (0.51) 34.92 (0.53) 49.17 (0.48) 47.33 (0.49)

To better visualize the estimates, Figure 1 plots heat maps of the true cell-type-specific co-expression matrices and estimates from Bulk, CSNet, s–bMIND and s–ENIGMA. The estimates from d–CSNet show similar patterns as CSNet plus some additional noises (see Figure S5). From Figure 1, it is clearly seen that Bulk, s–bMIND and s–ENIGMA give a less accurate view of the true co-expressions. Specifically, Bulk estimates high co-expressions in V3 while genes in V3 are not co-coexpressed in either cell type. True co-expression patterns in V2 from cell type 2 are also notably attenuated in Bulk. Moreover, s–bMIND does not perform well for cell type 2, the less abundant cell type. It is seen that the true co-expressions in V2 are not identified while co-expressions specific to cell type 1 are incorrectly inferred. s–ENIGMA also estimate high co-expressions in V3 and generally give correlations with large magnitude, potentially caused by the penalty used in ENIGMA, where cell-type-specific expressions are encouraged to be similar to the reference cell-type-specific expressions. In comparison, CSNet was able to identify the true co-expression patterns in both cell types.

To evaluate the threshold selection procedure in Section 2.3, we plot the ROC curves that plot the TPR against the FPR across a fine grid of thresholding parameters for Bulk, CSNet, s–bMIND, and s–ENIGMA. The thresholds selected by our proposed procedure in Section 2.3 are marked on the curves for CSNet. The ROC curves in Figures 2 show that CSNet achieves the best performance and the selected thresholds generally strike a reasonable balance between TPR and FPR. As shown in Tables 1,2 and Figures 1,2, the improvement of CSNet over others is the most notable for the less abundant cell type, and this demonstrates the efficacy of our proposed method for cell types whose signals are attenuated in bulk samples.

Fig. 2.

Fig. 2

ROC curves with a varying sample size n and network size p under a negative binomial distribution with a truncated AR(1) correlation structure in V1 or V2 (see Section 3). The four methods under comparison are Bulk, CSNet, s–bMIND and s–ENIGMA. The thresholds selected by CSNet are marked using red crosses on the curves.

We also consider a setting where there are K=4 cell types (see Section S3.5). To mimic microglia analyzed in Section 4, a less abundant cell type with important roles in Alzheimer’s disease (Tansey et al., 2018), we simulate a cell type with an average proportion of 10%. Table S6 shows that CSNet performed better than the other methods for this cell type. We also consider a setting with K=10 cell types that includes 6 rare cell types whose average proportions add up to 10% (see Section S3.5). This setting resembles our real data analysis in Section 4, as the brain tissue studied in our real data analysis have eight common brain cell types and the four least abundant cell types add up to less than 10%. Table S7 shows that the estimation and selection accuracy of CSNet on the four major cell types remained similar with the addition of 6 cell types when compared to Table S6.

3.2. Sensitivity Analysis of CSNet

In this section, we conduct a sensitivity analysis to examine the performance of our method when the cell type proportions πik’s used in CSNet are measured with biased noises. We consider n=600,p=100 and the same simulation setting as in Table S4 where the co-expression structures are those estimated from real data. Let πi1i=1n and π˜i1i=1n denote the true and noisy cell type proportions for cell type 1, respectively. We let

π˜i1=πi1+ei,eiNb×π1,κ×0.04,

where π1=i=1nπi1/n and b controls the magnitude of relative bias (e.g., b=0.2 indicates that cell type proportions are on average over-estimated by 20% in cell type 1). We consider b{0.2,0.1,0,0.1,0.2} and κ{0,0.6,0.9}. We threshold π˜i1 to be between [0,1] and set π˜i2=1π˜i1. To quantify the noise level, we adopt two metrics: Pearson correlation Corπi1,π˜i1 and relative root mean squared error (r-RMSE) 1ni=1nπi1π˜i12/π1. We present these metrics for cell type 1 as there are two cell types in the experiment. The noise levels in this sensitive analysis (see Table 3) are similar to those achieved by recently developed methods for estimating cell type proportions from bulk RNA-seq data. For example, Newman et al. (2019) and Chu et al. (2022) showed that the correlations between their estimated proportions and ground truth proportions, measured by technologies such as flow cytometry, were generally around 0.9.

Table 3.

Sensitivity analysis of CSNet with n=600 and p=100, under the same setting as Table S4. Noisy cell type proportions were set to πi1+Nb×π1,κ×0.04, and then thresholded to be within [0, 1]. We use Cor to denote the Pearson correlation Corπi1,π˜i1 and r-RMSE to denote the relative root mean squared error i=1nπi1π˜i12/n/π1.

Cell type 1 (m = 2/3) Cell type 2 (m = 1/3)
K b Cor r-RMSE F-norm Op.-norm FPR TPR F-norm Op.-norm FPR TPR
0.0 −0.2 1.00 0.26 1.32 (0.08) 0.57 (0.10) 0.05 (0.01) 0.42 (0.02) 2.56 (0.19) 1.54 (0.22) 0.07 (0.01) 0.43 (0.02)
−0.1 1.00 0.13 1.22 (0.09) 0.56 (0.10) 0.04 (0.01) 0.43 (0.02) 2.50 (0.19) 1.43 (0.22) 0.06 (0.01) 0.43 (0.02)
0.0 1.00 0.00 1.16 (0.09) 0.58 (0.12) 0.04 (0.01) 0.43 (0.02) 2.48 (0.18) 1.33 (0.23) 0.06 (0.01) 0.43 (0.02)
0.1 1.00 0.13 1.16 (0.09) 0.59 (0.12) 0.05 (0.01) 0.43 (0.02) 2.53 (0.17) 1.23 (0.22) 0.06 (0.01) 0.43 (0.02)
0.2 0.99 0.24 3.72 (0.31) 2.80 (0.32) 0.27 (0.02) 0.54 (0.04) 2.71 (0.16) 1.17 (0.21) 0.07 (0.01) 0.43 (0.03)
0.6 −0.2 0.96 0.30 10.63 (0.33) 10.07 (0.35) 0.31 (0.01) 0.55 (0.03) 10.26 (0.46) 9.26 (0.50) 0.35 (0.02) 0.56 (0.03)
−0.1 0.96 0.19 10.48 (0.29) 9.98 (0.31) 0.30 (0.02) 0.55 (0.04) 10.32 (0.49) 9.23 (0.53) 0.35 (0.01) 0.56 (0.03)
0.0 0.96 0.14 10.16 (0.27) 9.69 (0.29) 0.32 (0.02) 0.56 (0.04) 10.39 (0.54) 9.18 (0.58) 0.34 (0.01) 0.56 (0.03)
0.1 0.96 0.18 9.96 (0.26) 9.55 (0.27) 0.29 (0.01) 0.55 (0.03) 10.02 (0.61) 8.58 (0.65) 0.34 (0.02) 0.56 (0.03)
0.2 0.95 0.26 11.25 (0.22) 10.92 (0.22) 0.25 (0.02) 0.52 (0.04) 8.45 (0.58) 6.57 (0.64) 0.32 (0.01) 0.55 (0.03)
0.9 −0.2 0.83 0.40 20.85 (0.29) 20.47 (0.28) 0.17 (0.01) 0.44 (0.03) 26.50 (0.30) 25.88 (0.30) 0.20 (0.02) 0.42 (0.03)
−0.1 0.83 0.33 21.26 (0.27) 20.89 (0.27) 0.16 (0.01) 0.43 (0.02) 27.39 (0.34) 26.78 (0.34) 0.19 (0.02) 0.42 (0.03)
0.0 0.83 0.29 21.34 (0.25) 20.98 (0.25) 0.16 (0.01) 0.43 (0.03) 28.11 (0.36) 27.45 (0.34) 0.19 (0.01) 0.42 (0.03)
0.1 0.83 0.30 21.35 (0.23) 20.99 (0.22) 0.16 (0.01) 0.43 (0.02) 28.39 (0.34) 27.57 (0.34) 0.19 (0.01) 0.42 (0.03)
0.2 0.83 0.34 21.51 (0.20) 21.15 (0.20) 0.16 (0.01) 0.44 (0.03) 28.06 (0.36) 27.10 (0.38) 0.22 (0.01) 0.44 (0.03)

Table 3 below presents the sensitivity analysis results. It is seen that at any fixed value of k (i.e., noise variance), the estimation and selection errors are similar across different values of b (i.e., noise bias), suggesting that CSNet is not overly sensitive to biases. When k=0 (only bias, no random errors), the evaluation metrics are comparable to the case with accurate cell type proportions (i.e., κ=b=0). When κ=0.6, the TPRs remain high in both cell types with a reasonable false positive control, though the estimation errors increase. When κ=0.9, the correlations can be as low as 0.83 and r-RMSE can be as large as 0.40, suggesting a considerable amount of noises in cell type proportions. Though the estimation errors increase, the FPRs and TPRs remain reasonably satisfactory.

4. Cell-type-specific Co-expressions of Different Gene Sets for an Alzheimer’s Disease Cohort

We focus on estimating cell-type-specific co-expressions using bulk RNA-seq data from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP) study on Alzheimer’s disease (Bennett et al., 2018). Gene expressions were profiled by bulk RNA-seq for n=541 postmortem brain samples, expression unit FPKM (Trapnell et al., 2010) was used to quantify gene expressions, and no notable batch effects were observed from these samples (see Figure S6). The cell type proportions for K=8 cell types were estimated using CIBERSORTx (Newman et al., 2019) with the signature matrix built from the single nucleus RNA-seq data (Mathys et al., 2019) collected on the same brain region in a subset of 48 samples.

We applied CSNet as defined in (9), with the tuning parameters selected using the cross validation procedure discussed in Section 2.3, to estimate cell-type-specific co-expressions for all K=8 cell types. Additionally, we compared CSNet to two alternative approaches, one through s–bMIND, the best performing alternative in Section 3, and one using single cell data (Mathys et al., 2019), respectively. For s–bMIND estimates, we followed Wang et al. (2021a) to infer priors from single cell data and supplied these priors to estimate cell-type-specific expressions in each sample; see details in Section S4; correlation estimates were then computed using the estimated cell-type-specific expressions across different samples. To estimate cell-type-specific co-expressions from single cell data, we first calculated cell-type-specific expressions in each sample. Specifically, the expression profile of gene j in cell type k for sample i was calculated by first summing over the UMI counts of gene j from all cells of cell type k in sample i, and then normalized by the total number of UMI counts in cell type k from sample i. These cell-type-specific expressions calculated for different samples were then used to estimate the co-expression (i.e., correlation matrix) in each cell type, and the correlation matrices were further thresholded following the procedure in Rothman et al. (2009) with the SCAD penalty. For all methods, we visualized the estimated co-expressions using heat maps, with genes ordered into clusters (or modules) identified by WGCNA (Langfelder and Horvath, 2008), a gene clustering method, applied to bulk samples. In the ensuing analysis, we focus on the four most abundant cell types: excitatory neuron (Ex), oligodendrocyte (Oli), astrocyte (Ast) and microglia (Mic). The average proportions for these four cell types are 0.50, 0.19, 0.20, 0.08, respectively.

4.1. Gene Sets with Known Cell-type-specific Functions

The gene co-expressions estimated from different methods were compared on a few sets of genes. We first considered three sets of genes obtained from Gene Ontology (GO) (Ashburner et al., 2000; Consortium, 2021) including the excitatory synapse genes (GO:0060076, p=46), myelin sheath genes (GO:0043209, p=42) and astrocyte differentiation genes (GO:0048708,p=72), primarily functioning in excitatory neurons, oligodendrocytes and astrocytes, respectively. Specifically, the excitatory synapse gene set contains genes whose products function mainly in excitatory synapses, and the myelin sheath gene set has genes related to myelin sheath, which is supplied by oligodendrocytes to the central nervous system; the astrocyte differentiation gene set contains genes involved in the differentiation process of an astrocyte. These gene sets, according to their GO definitions, are expected to express and/or co-express primarily in the cell types that are relevant to their functions. In our analysis of these three gene sets, we focused on genes expressed in more than 25% of the ROSMAP bulk samples, resulting in sets of sizes p=45, 41and68, respectively.

Figure 3 shows the co-expression estimates from Bulk, CSNet and s–bMIND for the excitatory synapse gene set. It is seen that CSNet identified co-expressions specific to excitatory neurons, while s–bMIND suggested similar co-expression patterns in all four cell types. We also estimated cell-type-specific co-expressions for the myelin sheath and astrocyte differentiation gene sets, shown in Figures S7 and S8, respectively. These plots show that CSNet identified co-expressions specific to oligodendrocytes and astrocytes, respectively, while s–bMIND again estimated similar co-expressions across four cell types. We also conducted an analysis that simultaneously considers all three GO gene sets and found that CSNet can distinguish the three gene sets in the corresponding cell types (Figure S9). In comparison, the bulk estimates cannot distinguish them and the co-expressions of myelin sheath and astrocyte differentiation gene sets are much weaker (Figure S9), suggesting that bulk estimates may miss co-expressions from these less abundant cell types. Finally, Figure 4 shows that the estimates based on single cell data are noisy and do not show any cell-type-specific co-expression patterns. Also in Figure 4, for all three gene sets, the strongest co-expressions are always observed in excitatory neurons, likely driven by the fact that it is the most abundant cell type (Mathys et al., 2019).

Fig. 3.

Fig. 3

Co-expressions of excitatory synapse genes in different cell types. From left to right: (a) sample correlation matrix estimated from bulk RNA-seq data, (b) CSNet estimates and (c) s–bMIND estimates. For s–bMIND, genes with constant expression estimates across samples are marked in gray.

Fig. 4.

Fig. 4

Co-expressions of excitatory synapse, myelin sheath and astrocyte differentiation genes in different cell types, estimated using the ROSMAP single cell data (Mathys et al., 2019). Marked in gray are genes with no variation or no expression within a given cell type.

4.2. Alzheimer’s Disease Risk Gene Set

Next, we focused on Alzheimer’s disease risk genes from GWAS (see gene names in Table 4), which capture around 50% of the heritability in late-onset AD (Sims et al., 2020). Our analysis focused on 61 genes with an FPKM greater than 0.1 in at least 50 ROSMAP samples. There is a growing literature on the molecular mechanisms and related cell types for these risk genes. Besides the well studied pathways of amyloid-β and tau processing, several other pathways have also been implicated (Pimenova et al., 2018; Sims et al., 2020), among which neuroinflammation was recently highlighted as one of the most important causal pathways in Alzheimer’s disease (Heneka et al., 2015). Both microglia and astrocyte are the key cell types involved in such immune responses, and microglia, the innate immune cells in central nervous system, was prioritized as the cell type most enriched for GWAS associations (Skene and Grant, 2016; Tansey et al., 2018). Our analysis aims to use CSNet to explore the cell-type-specific co-expression patterns among these Alzheimer’s disease risk genes.

Table 4.

The list of Alzheimer’s disease risk genes. Gene names are displayed by cluster and in the same order as they appear in Figure 5. Our analysis included only the sequenced genes with an FPKM greater than 0.1 in at least 50 ROSMAP samples.

Cluster Genes
1 MEF2C, PILRA, MS4A8, EPHA1, IL34, CELF1, KAT8, KANSL1, HS3ST1, ACE, PTK2B, MAPT, NDUFAF7, TSPOAP1-AS1, SLC24A4, SORL1, PPARGC1A, C17orf107, APP, TPBG, CNTNAP2
2 IGHG3, HLA-DRB1, TRIP4, CASS4, MS4A14, PLCG2, INPP5D, SCIMP, MS4A7, CD33, TREM2, MS4A4A, MS4A6A, ABI3, SPI1
3 PRKD3, TP53INP1, CD2AP, ZNF423, CLU, SPPL2A, FERMT2, IQCK, RORA, ECHDC3
4 APOE, MS4A4E, ZCWPW1, ABCA7, BIN1, SHARPIN
5 HESX1, APH1B, ADAM10, PICALM, ZNF655
6 CR1, HBEGF, ADAMTS1, ADAMTS4

Figure 5 shows the estimates from Bulk, d–CSNet and CSNet, respectively. We applied the one standard error rule when selecting the tuning parameters for less abundant cell types (Section S3.2). The s–bMIND estimates are again similar across cell types, and are relegated to Figure S(10)a in the supplement. In Figure 5, some within cluster co-expressions from bulk samples are no longer seen in the cell-type-specific estimates, likely due to the confounding effect of cell type proportions. The d–CSNet and CSNet estimates in Figures 5(b) and (c) show that genes in Cluster 4 (colored in yellow) were co-expressed in astrocytes. This gene cluster includes APOE, a major Alzheimer’s disease risk gene known to be highly expressed in astrocytes (Yamazaki et al., 2019). APOE protein is primarily produced in astrocytes, which then interacts with amyloid-β, which is involved in a central pathway of Alzheimer’s disease (Yamazaki et al., 2019). Besides, both APOE and ABCA7 contribute to lipid metabolism and phagocytosis (Pimenova et al., 2018), consistent with their high co-expressions found in Cluster 4. The CSNet estimates for Cluster 4 further highlight their connections with several other Alzheimer’s disease risk genes in astrocytes. Additionally, the d–CSNet and CSNet estimates in Figures 5(b) and (c) suggest that genes in Cluster 2 (colored in blue) were co-expressed in microglia, a finding supported by existing literature on Alzheimer’s disease. Firstly, 9 out of 15 genes in Cluster 2 are known to be involved in neuroinflammation and Alzheimer’s disease mechanisms via microglia. Among them, the coding variants in PLCG2, TREM2, ABI3 implicate innate immunity in Alzheimer’s disease as mediated by microglia (Sims et al., 2017); CD33 inhibits the uptake of amyloid-β in microglia (Griciuc et al., 2013); MS4A gene cluster is a key modulator of TREM2 in microglia (Deming et al., 2019) and SPI1 is a central regulator of microglia expression and Alzheimer’s disease risk (Kosoy et al., 2021). In addition, 9 genes are known to express uniquely in microglia, including HLA-DRB1, PLCG2, CD33, TREM2, ABI3 and the MS4A gene cluster (Sims et al., 2017; Pimenova et al., 2018). The d–CSNet and CSNet estimates were able to identify cell-type-specific co-expression patterns of these genes, while single cell data based estimates could not (see Figure S10(b)), which possibly offered new insights into regulations of Alzheimer’s disease risk genes. The estimated co-expressions in gene Clusters 2 and 4 reveal previously unknown cell-type-specific co-expressions among Alzheimer’s disease risk genes, and may suggest cell-type-specific disease mechanisms.

Fig. 5.

Fig. 5

Co-expression networks of Alzheimer’s disease risk genes inferred from the ROSMAP data. From left to right: sample correlation matrix estimated from bulk RNA-seq data, d–CSNet estimates, and CSNet estimates.

Finally, the sensitivity analysis in Section S5.1 shows that CSNet remained robust as a reasonable amount of noise was added to the cell type proportions. We have also conducted a negative control experiment where cell type proportion vectors for different samples were randomly permuted. Figure S14 shows that the resulting estimates in excitatory neurons, the most abundant cell type, always resemble the bulk co-expression estimate, while the previously uncovered cell-type-specific co-expression patterns are no longer seen.

5. Discussion

Our model (1) is designed for gene expression data measured by the RNA-seq protocol, where sequencing read counts capture the expression levels for all cells in a tissue sample. We caution that the same model may not be applicable to microarray data, where expression levels have been transformed for normalization (Zhong and Liu, 2012).

We have assumed that the cell type proportions πik’s are given in our analysis. In practice, they are estimated with existing methods such as Newman et al. (2019) and Chu et al. (2022), where it is shown that the correlations between their estimated proportions and ground truth proportions were generally around 0.9. Our empirical investigations showed that CSNet is not overly sensitive to errors in πik’s (see sensitivity analysis in Sections 3.2 and S5.1). It is possible to further extend our framework to accommodate noisy πik’s. In this case, we may further consider the σjj(k)’s to be estimated from zijzij=k=1Kπˆik2σjj(k)+ξijj,j,j[p], where ξijj=ϵijj+k=1Kπik2πˆik2σjj(k). Hence, if the error πik2πˆik2 is small, σjj(k) should still be well estimated. We leave the full investigation of this topic as future research.

Our proposed work focuses on the estimation of correlation matrices R(k)’s that characterize marginal associations amongst genes. It may also be of interest to estimate the precision matrix defined as Ω(k)=Σ(k)1. Under the Gaussian assumption, a zero (nonzero) entry in Ω(k) indicates independence (dependence) between two genes conditional on all other genes. Without making the Gaussian assumption, the nonzero entries in Ω(k) characterize partial correlations instead of conditional dependence. Under our framework, one feasible approach to estimate Ω(k)’s is to consider

minΩ(k)Σ(k)Ω(k)IF2+𝒫λkΩ(k) (10)

where Σ(k) is estimated from the first step of CSNet and 𝒫λk() is a sparse penalty function. This type of problems can be solved, for example, using the CLIME method (Cai et al., 2011). The formulation in (10) may incur a high computational cost, and the results can be sensitive to the selection of gene sets. We leave a full investigation of (10) to future work. In our current work, we focus on a co-expression network due to its computational efficiency, model flexibility and wide adoption in biomedical research (Langfelder and Horvath, 2008).

In terms of estimation, instead of the two-step procedure considered in CSNet, an alternative approach is to integrate these two steps and consider

i=1nj,jzijzijkπik2σjj(k)2+k=1Kjj𝒫λkσjj(k)/σjj(k)σjj(k), (11)

where 𝒫λ(x) denotes a penalty function, such as lasso or SCAD, with a regularization parameter λ. Estimating σjj(k)’s from (11) can be computationally costly, as there are OKp2 parameters to optimize together and it is necessary to tune the regularization parameters λ1,,λK jointly. In comparison, the two-step procedure in CSNet allows for a separate tuning of λk, and given the tuning parameters, the computational complexity of CSNet is comparable to that of naive covariance estimators for i.i.d. samples. While the two-step procedure in CSNet is not guaranteed to optimize (11), it is highly computationally efficient, which is appealing for practitioners. We also show in Theorem S1.1 that the error rate of CSNet is comparable to that of estimating sparse covariance matrices directly from i.i.d. samples (Rothman et al., 2008). For finite sample cases, it may be desirable to ensure the positive definiteness of the final estimator. One strategy is to solve a constrained optimization problem, subject to positive definiteness, to find the nearest correlation matrix in Frobenius norm. This can be carried out efficiently using existing solvers (e.g., Qi and Sun, 2006; Sun and Vandenberghe, 2015).

Some recent methods have been developed to estimate cell-specific co-expression networks using single cell data, including Dai et al. (2019) and (Wang et al., 2021d). It is important to note that cell-specific and cell-type-specific networks do not necessarily capture the same type of correlation of expression levels. For example, if two genes have the same expression level for all cells in a tissue sample and this expression level varies from sample to sample, then these two genes are not correlated in the cell-specific networks but are highly correlated in the network estimated using bulk samples, and this correlation may be due to regulations (e.g., genetic variants) at the sample level. Moreover, cell-specific network estimates may be subject to noises and may require averaging to facilitate interpretation (Wang et al., 2021d).

Recently, new computational tools have been developed to more accurately estimate the proportions of cell subtypes in bulk tissues, such as Chu et al. (2022) and Huang et al. (2023). Our proposed method can also be combined with these estimates to understand co-expressions in cell subtypes and to address potential confounding due to cell subtypes.

Finally, with an increasing number of studies collecting single cell data, we may also obtain more accurate co-expression estimates. For example, if a more accurate or refined reference signature matrix is available from the new single cell studies, one can generate updated cell type proportion estimates for bulk data (Newman et al., 2019) and use them in our procedure. As cells can be annotated into cell types, statistical methods have also been developed to directly infer cell-type-specific co-expression networks from single cell data, such as Su et al. (2022); Lu and Keles (2023). Moreover, an integrated analysis of bulk and single cell data may also improve the co-expression estimates. For example, bMIND and ENIGMA have explored ways to extract information from single cell data to help with the estimation. However, platform differences and batch effects are prominent in integration, and have not been addressed well in these methods. We plan to explore along this direction in our future research.

Supplementary Material

Supp 1
Supp 2

Acknowledgements

We thank the ROSMAP project for their permission, requested at https://www.radc.rush.edu, to access the bulk and single nucleus RNA-seq data in the project. The ROSMAP project is supported by the following grants: P30AG72975, P30AG010161 (ADCC), R01AG015819 (RISK), R01AG017917 (MAP), U01AG46152 (AMP-AD Pipeline I) and U01AG61356 (AMP-AD Pipeline II). Su and Zhao were supported in part by NIH grants R01 GM134005 and R56 AG074015. Zhang was supported by NSF grant DMS 2210469 and DMS 2329296.

Footnotes

Conflict-of-Interest Statements

The authors report there are no competing interests to declare.

References

  1. Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, and Clark HF (2009), “Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus,” PloS one, 4, e6098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alzheimer’s Association (2019), “2019 Alzheimer’s disease facts and figures,” Alzheimer’s & dementia, 15, 321–387. [Google Scholar]
  3. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. (2000), “Gene ontology: tool for the unification of biology,” Nature genetics, 25, 25–29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, and Schneider JA (2018), “Religious orders study and rush memory and aging project,” Journal of Alzheimer’s disease, 64, S161–S189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bickel PJ and Levina E (2008a), “Covariance regularization by thresholding,” The Annals of Statistics, 36, 2577–2604. [Google Scholar]
  6. Bickel PJ and Levina E (2008b), “Regularized estimation of large covariance matrices,” The Annals of Statistics, 36, 199–227. [Google Scholar]
  7. Cai T, Liu W, and Luo X (2011), “A constrained l1 minimization approach to sparse precision matrix estimation,” Journal of the American Statistical Association, 106, 594–607. [Google Scholar]
  8. Cai Z and Xiao M (2016), “Oligodendrocytes and Alzheimer’s disease,” International Journal of Neuroscience, 126, 97–104. [DOI] [PubMed] [Google Scholar]
  9. Chu T, Wang Z, Pe’er D, and Danko CG (2022), “Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology,” Nature Cancer, 3, 505–517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cobos FA, Alquicira-Hernandez J, Powell JE, Mestdagh P, and De Preter K (2020), “Benchmarking of cell type deconvolution pipelines for transcriptomics data,” Nature communications, 11, 1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Consortium TGO (2021), “The Gene Ontology resource: enriching a GOld mine,” Nucleic Acids Research, 49, D325–D334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dai H, Li L, Zeng T, and Chen L (2019), “Cell-specific network constructed by single-cell RNA sequencing data,” Nucleic acids research, 47, e62–e62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. De Strooper B and Karran E (2016), “The cellular phase of Alzheimer’s disease,” Cell, 164, 603–615. [DOI] [PubMed] [Google Scholar]
  14. Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, Li Z, Del-Aguila JL, Dube U, Farias FG, et al. (2019), “The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk,” Science translational medicine, 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Denisenko E, Guo BB, Jones M, Hou R, De Kock L, Lassmann T, Poppe D, Clément O, Simmons RK, Lister R, et al. (2020), “Systematic assessment of tissue dissociation and storage biases in single-cell and singlenucleus RNA-seq workflows,” Genome biology, 21, 1–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dong M, Thennavan A, Urrutia E, Li Y, Perou CM, Zou F, and Jiang Y (2021), “SCDC: bulk gene expression deconvolution by multiple single-cell RNA sequencing references,” Briefings in bioinformatics, 22, 416–427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. El Karoui N. (2008), “Operator norm consistent estimation of large-dimensional sparse covariance matrices,” The Annals of Statistics, 36, 2717–2756. [Google Scholar]
  18. Fan J and Li R (2001), “Variable selection via nonconcave penalized likelihood and its oracle properties,” Journal of the American statistical Association, 96, 1348–1360. [Google Scholar]
  19. Fujita M, Gao Z, Zeng L, McCabe C, White CC, Ng B, Green GS, Rozenblatt-Rosen O, Phillips D, Amir-Zilberstein L, et al. (2022), “Cell subtype specific effects of genetic variation in the aging and Alzheimer cortex,” bioRxiv, 2022–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gaiteri C, Ding Y, French B, Tseng GC, and Sibille E (2014), “Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders,” Genes, brain and behavior, 13, 13–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, and Tanzi RE (2013), “ Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta,” Neuron, 78, 631–643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW, et al. (2009), “Histone modifications at human enhancers reflect global cell-type-specific gene expression,” Nature, 459, 108–112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. (2015), “Neuroinflammation in Alzheimer’s disease,” The Lancet Neurology, 14, 388–405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Huang P, Cai M, Lu X, McKennan C, and Wang J (2023), “Accurate estimation of rare cell type fractions from tissue omics data via hierarchical deconvolution,” bioRxiv, 2023–03. [Google Scholar]
  25. Hwang B, Lee JH, and Bang D (2018), “Single-cell RNA sequencing technologies and bioinformatics pipelines,” Experimental & molecular medicine, 50, 1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Jew B, Alvarez M, Rahmani E, Miao Z, Ko A, Garske KM, Sul JH, Pietiläinen KH, Pajukanta P, and Halperin E (2020), “Accurate estimation of cell composition in bulk expression through robust integration of single-cell information,” Nature communications, 11, 1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Jiang B. (2013), “Covariance selection by thresholding the sample correlation matrix,” Statistics & Probability Letters, 83, 2492–2498. [Google Scholar]
  28. Kiselev VY, Andrews TS, and Hemberg M (2019), “Challenges in unsupervised clustering of single-cell RNA-seq data,” Nature Reviews Genetics, 20, 273–282. [DOI] [PubMed] [Google Scholar]
  29. Kosoy R, Fullard J, Zeng B, Bendl J, Dong P, Rahman S, Kleopoulos S, Shao Z, Humphrey J, de Paiva Lopes K, et al. (2021), “Genetics of the human microglia regulome refines Alzheimer’s disease risk loci,” medRxiv. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Langfelder P and Horvath S (2008), “WGCNA: an R package for weighted correlation network analysis,” BMC bioinformatics, 9, 1–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al. (2016), “Comprehensive analyses of tumor immunity: implications for cancer immunotherapy,” Genome biology, 17, 1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Love MI, Huber W, and Anders S (2014), “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2,” Genome biology, 15, 1–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lu S and Keles S (2023), “Debiased personalized gene coexpression networks for population-scale scRNA-seq data,” Genome Research, gr–277363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, et al. (2019), “Single-cell transcriptomic analysis of Alzheimer’s disease,” Nature, 570, 332–337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Meng G and Mei H (2019), “Transcriptional dysregulation study reveals a core network involving the progression of Alzheimer’s disease,” Frontiers in aging neuroscience, 11, 101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Morabito S, Miyoshi E, Michael N, Shahin S, Martini AC, Head E, Silva J, Leavy K, Perez-Rosendahl M, and Swarup V (2021), “Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease,” Nature Genetics, 53, 1143–1155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Mostafavi S, Gaiteri C, Sullivan SE, White CC, Tasaki S, Xu J, Taga M, Klein H-U, Patrick E, Komashko V, et al. (2018), “A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer’s disease,” Nature neuroscience, 21, 811–819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, and Alizadeh AA (2015), “Robust enumeration of cell subsets from tissue expression profiles,” Nature methods, 12, 453–457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, et al. (2019), “Determining cell type abundance and expression from bulk tissues with digital cytometry,” Nature biotechnology, 37, 773–782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Pimenova AA, Raj T, and Goate AM (2018), “Untangling genetic risk for Alzheimer’s disease,” Biological psychiatry, 83, 300–310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Qi H and Sun D (2006), “A quadratically convergent Newton method for computing the nearest correlation matrix,” SIAM journal on matrix analysis and applications, 28, 360–385. [Google Scholar]
  42. Rothman AJ, Bickel PJ, Levina E, and Zhu J (2008), “Sparse permutation invariant covariance estimation,” Electronic Journal of Statistics, 2, 494–515. [Google Scholar]
  43. Rothman AJ, Levina E, and Zhu J (2009), “Generalized thresholding of large covariance matrices,” Journal of the American Statistical Association, 104, 177–186. [Google Scholar]
  44. Sims R, Hill M, and Williams J (2020), “The multiplex model of the genetics of Alzheimer’s disease,” Nature neuroscience, 23, 311–322. [DOI] [PubMed] [Google Scholar]
  45. Sims R, Van Der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, et al. (2017), “Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease,” Nature genetics, 49, 1373–1384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Skene NG and Grant SG (2016), “Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment,” Frontiers in neuroscience, 10, 16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Stower H. (2019), “Single-cell insights into neurology,” Nature medicine, 25, 1799–1799. [DOI] [PubMed] [Google Scholar]
  48. Su C, Xu Z, Shan X, Cai B, Zhao H, and Zhang J (2022), “Cell-type-specific co-expression inference from single cell RNA-sequencing data,” bioRxiv, 2022–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Sun T, Song D, Li WV, and Li JJ (2021), “scDesign2: a transparent simulator that generates high-fidelity single-cell gene expression count data with gene correlations captured,” Genome biology, 22, 1–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Sun Y and Vandenberghe L (2015), “Decomposition methods for sparse matrix nearness problems,” SIAM Journal on Matrix Analysis and Applications, 36, 1691–1717. [Google Scholar]
  51. Tang D, Park S, and Zhao H (2020), “NITUMID: nonnegative matrix factorization-based immune-TUmor MIcroenvironment Deconvolution,” Bioinformatics, 36, 1344–1350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Tansey KE, Cameron D, and Hill MJ (2018), “Genetic risk for Alzheimer’s disease is concentrated in specific macrophage and microglial transcriptional networks,” Genome medicine, 10, 1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Tian J, Wang J, and Roeder K (2021), “ESCO: single cell expression simulation incorporating gene co-expression,” Bioinformatics, 37, 2374–2381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, Van Baren MJ, Salzberg SL, Wold BJ, and Pachter L (2010), “Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation,” Nature biotechnology, 28, 511–515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Wan Y-W, Al-Ouran R, Mangleburg CG, Perumal TM, Lee TV, Allison K, Swarup V, Funk CC, Gaiteri C, Allen M, et al. (2020), “Metaanalysis of the Alzheimer’s disease human brain transcriptome and functional dissection in mouse models,” Cell reports, 32, 107908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Wang J, Roeder K, and Devlin B (2021a), “Bayesian estimation of cell type-specific gene expression with prior derived from single-cell data,” Genome Research, gr–268722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Wang M, Li A, Sekiya M, Beckmann ND, Quan X, Schrode N, Fernando MB, Yu A, Zhu L, Cao J, et al. (2021b), “Transformative network modeling of multi-omics data reveals detailed circuits, key regulators, and potential therapeutics for Alzheimer’s disease,” Neuron, 109, 257–272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Wang M, Roussos P, McKenzie A, Zhou X, Kajiwara Y, Brennand KJ, De Luca GC, Crary JF, Casaccia P, Buxbaum JD, et al. (2016), “Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer’s disease,” Genome medicine, 8, 1–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Wang W, Yao J, Wang Y, Zhang C, Tao W, Zou J, and Ni T (2021c), “Improved estimation of cell type-specific gene expression through deconvolution of bulk tissues with matrix completion,” bioRxiv, 2021–06. [Google Scholar]
  60. Wang X, Choi D, and Roeder K (2021d), “Constructing local cell-specific networks from single-cell data,” Proceedings of the National Academy of Sciences, 118, e2113178118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Wang X, Park J, Susztak K, Zhang NR, and Li M (2019), “Bulk tissue cell type deconvolution with multi-subject single-cell expression reference,” Nature communications, 10, 1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, et al. (2016), “Defeating Alzheimer’s disease and other dementias: a priority for European science and society,” The Lancet Neurology, 15, 455–532. [DOI] [PubMed] [Google Scholar]
  63. Yamazaki Y, Zhao N, Caulfield TR, Liu C-C, and Bu G (2019), “Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies,” Nature Reviews Neurology, 15, 501–518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Yang T, Alessandri-Haber N, Fury W, Schaner M, Breese R, LaCroix-Fralish M, Kim J, Adler C, Macdonald LE, Atwal GS, et al. (2021), “AdRoit is an accurate and robust method to infer complex transcriptome composition,” Communications Biology, 4, 1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Zhang B, Gaiteri C, Bodea L-G, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, et al. (2013), “Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease,” Cell, 153, 707–720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Zhang B and Horvath S (2005), “A general framework for weighted gene coexpression network analysis,” Statistical applications in genetics and molecular biology, 4. [DOI] [PubMed] [Google Scholar]
  67. Zhong Y and Liu Z (2012), “Gene expression deconvolution in linear space,” Nature methods, 9, 8–9. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supp 1
Supp 2

RESOURCES